Results 51 to 60 of about 15,684 (181)

Alteration of Methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120 [PDF]

Journal of Neuroscience Methods, 2010
The use of drugs for recreational purposes, in particular Methamphetamine, is associated with an increased risk of infection with human immunodeficiency virus (HIV)-1. HIV-1 infection in turn can lead to HIV-associated neurological disorders (HAND) that range from mild cognitive and motor impairment to HIV-associated dementia (HAD). Interestingly, post
Amanda J, Roberts, Ricky, Maung, Natalia E, Sejbuk, Christopher, Ake, Marcus, Kaul   +4 more
openaire   +2 more sources

Helix-A peptide prevents gp120-mediated neuronal loss

Molecular Brain, 2019
Aim The human-immunodeficiency virus (HIV) envelope protein gp120 promotes synaptic damage similar to that observed in people living with HIV who have neurocognitive disorders.
Valeria Avdoshina, Francesca Taraballi, Ennio Tasciotti, Aykut Üren, Italo Mocchetti   +4 more
doaj   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

HIV Medicine, Volume 27, Issue 4, Page 498-512, April 2026.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre, Antoine Gross, Alain Makinson   +2 more
wiley   +1 more source

PET imaging of HIV-1 envelope protein gp120 using 18F-labeled nanobodies

iScience
Radiolabeled antibodies against the HIV-1 envelope protein, gp120, have been previously tested in animal models and in people with HIV (PWH). Nanobodies offer advantages over antibodies, including smaller size and faster clearance, which allow labeling with fluorine-18.
Neysha Martinez-Orengo, Swati Shah, Jianhao Lai, Falguni Basuli, Anna Lyndaker, Mitchell L. Turner, Morteza Peiravi, Suman Sourabh, Kevon Sampson, Peng Zhang, Rolf E. Swenson, Paolo Lusso, Frank Maldarelli, Avindra Nath, Chuen-Yen Lau, Dima A. Hammoud   +15 more
openaire   +3 more sources

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein

PLOS Computational Biology, 2016
Heavy glycosylation of the envelope (Env) surface subunit, gp120, is a key adaptation of HIV-1; however, the precise effects of glycosylation on the folding, conformation and dynamics of this protein are poorly understood. Here we explore the patterns of HIV-1 Env gp120 glycosylation, and particularly the enrichment in glycosylation sites proximal to ...
Jianhui Tian, Cesar A López, Cynthia A Derdeyn, Morris S Jones, Abraham Pinter, Bette Korber, S Gnanakaran   +6 more
openaire   +4 more sources

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41

Retrovirology, 2004
Background We previously described the construction of an HIV-1 envelope glycoprotein complex (Env) that is stabilized by an engineered intermolecular disulfide bond (SOS) between gp120 and gp41.
Caffrey Michael, Busser Els, Dankers Martijn M, Sanders Rogier W, Moore John P, Berkhout Ben   +5 more
doaj   +1 more source

A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. [PDF]

PLoS ONE, 2012
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox vector and an HIV envelope protein with alum, as shown in the RV144 trial.
Laura Pattacini, Gregory J Mize, Jessica B Graham, Tayler R Fluharty, Tisha M Graham, Karen Lingnau, Benjamin Wizel, Beatriz Perdiguero, Mariano Esteban, Giuseppe Pantaleo, Mingchao Shen, Gregory A Spies, M Juliana McElrath, Jennifer M Lund   +13 more
doaj   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

Advanced Functional Materials, Volume 36, Issue 26, 30 March 2026.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras, Imelda Raczkiewicz, Peggy Bouquet, Jean‐Philippe Dacquin, Jeremy Dhainaut, Anne Goffard, Christophe Volkringer   +6 more
wiley   +1 more source

Mutant CD4 Molecules with Improved Binding to HIV Envelope Protein gp120 Selected by Phage Display

Virology, 1997
Phage-display methodology has been used to select variant CD4 proteins exhibiting increased binding to the surface envelope glycoprotein, gp120, of Human Immunodeficiency Virus Type-1. To facilitate the selection, a library of mutant CD4 proteins was constructed by cloning a PCR-generated error prone population of the first two domains of CD4 into the ...
Krykbaev, Rustem, McKeating, Jane, Jones, Ian   +2 more
openaire   +2 more sources